BioSpace News Archive

According to Precedence Research, the medical implants market size is poised to grow at a CAGR of 5.4% during the forecast period and to reach valuation US$ 137.5 billion by 2029.

The pharmaceutical logistics market is projected to garner grow at a CAGR of 8.3% during the forecast period and expected to reach over US$ 159.14 billion by 2030.

Moderna, Inc. announced that it has received approval from the US FDA for its amendment to the emergency use authorization to allow for a second booster dose of its COVID-19 vaccine at the 50 µg dose level in adults 50 years of age and older who have received an initial booster of any of the authorized or approved COVID-19 vaccines and adults 18 years of age and older with certain kinds of immunocompromise.

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use of their COVID-19 vaccine to include a second booster dose in adults ages 50 years and older who have previously received a first booster of any authorized COVID-19 vaccine.

Genetic or DNA testing usually refers to medical tests that examine and evaluates the changes in chromosomes, genes, or several types of proteins to help a person’s chance of developing one or rule out a suspected genetic condition.

Cytovia Therapeutics, Inc. announced today that its leadership team will present at the following upcoming conferences.

According to Report, the regenerative medicine market size is predicted to surpass around USD 33.57 billion by 2029 and growing at a CAGR of 16.2% from 2021 to 2030.

However, the patent expiration of biologic products opens opportunities for the development of biosimilars. Biosimilars are the biologic drugs which resembles the marketed biological in terms of their quality specifications, safety profile, and efficacy parameters.

BioCurity is a private preclinical biotech company developing supportive cancer oncology drugs to prevent or mitigate some of the side effects of radiation therapy for cancer patients.

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), today announced the publication of comparative data between two different dialysis circuit anticoagulants in pediatric patients undergoing continuous renal replacement therapy (CRRT).